The impact of disease severity on efficacy from a Phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)

被引：0
|
作者：
Kenney, C. [1 ]
French, J. [2 ]
Porter, R. [3 ]
Perucca, E. [4 ]
Brodie, M. [5 ]
Rogawski, M. [6 ]
Harden, C. [1 ]
Rosenblut, C. Luzon [1 ]
Qian, J. [1 ]
Leung, J. [1 ]
Beatch, G. [1 ]
机构：
[1] Xenon Pharmaceut Inc, Burnaby, BC, Canada
[2] NYU, Langone Comprehens Epilepsy Ctr, New York, NY USA
[3] Univ Pennsylvania, Philadelphia, PA USA
[4] Monash Univ, Melbourne, Australia
[5] Univ Dept Med & Therapeut, Glasgow, Lanark, Scotland
[6] Univ Calif Davis, Sch Med, Davis, CA USA
来源：
EPILEPSIA | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
449
引用
收藏
页码：136 / 136
页数：1
相关论文
共 13 条
  • [1] The Impact of Disease Severity on Efficacy from a Phase 2b Study of XEN1101, A Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)
    Kenney, Christopher
    French, Jacqueline
    Porter, Roger
    Perucca, Emilio
    Brodie, Martin
    Rogawski, Michael A.
    Harden, Cynthia
    Qian, Jenny
    Beatch, Greg
    NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1428
  • [2] Rapid onset of efficacy of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: Results from a phase 2b study (X-TOLE)
    Kenney, C.
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M.
    Harden, C.
    Rosenblut, C. Luzon
    Qian, J.
    Leung, J.
    Beatch, G.
    EPILEPSIA, 2022, 63 : 136 - 136
  • [3] Phase 2b Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal onset seizures (X-TOLE)
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M.
    Pimstone, S.
    Aycardi, E.
    Harden, C.
    Xu, Y.
    Rosenblut, C. Luzon
    Kenney, C.
    Beatch, G.
    EPILEPSIA, 2022, 63 : 117 - 118
  • [4] Phase 2B Efficacy and Safety of XEN1101, a Novel Potassium Channel Modulator, In Adults with Focal Epilepsy (X-TOLE)
    French, Jacqueline
    Porter, Roger
    Perucca, Emilio
    Brodie, Martin
    Rogawski, Michael A.
    Pimstone, Simon
    Aycardi, Ernesto
    Harden, Cynthia
    Xu, Yi
    Rosenblut, Constanza Luzon
    Kenney, Christopher
    Beatch, Greg
    NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1427
  • [5] Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
    French, Jacqueline A.
    Porter, Roger J.
    Perucca, Emilio
    Brodie, Martin J.
    Rogawski, Michael A.
    Pimstone, Simon
    Aycardi, Ernesto
    Harden, Cynthia
    Qian, Jenny
    Luzon Rosenblut, Constanza
    Kenney, Christopher
    Beatch, Gregory N.
    JAMA NEUROLOGY, 2023, 80 (11) : 1145 - 1154
  • [6] XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M. A.
    Harden, C.
    Qian, J.
    Luzon-Rosenblut, C.
    Kenney, C.
    Beatch, G. N.
    EPILEPSIA, 2023, 64 : 275 - 276
  • [7] XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy
    French, Jacqueline
    Porter, Roger
    Perucca, Emilio
    Brodie, Martin
    Rogawski, Michael
    Harden, Cynthia
    Qian, Jenny
    Luzon-Rosenblut, Constanza
    Kenney, Christopher
    Beatch, Gregory
    NEUROLOGY, 2023, 100 (17)
  • [8] XEN1101, a novel potassium channel opener: hope or hype for adults with focal seizure
    Fareed, Areeba
    Sohail, Afra
    Siddiqui, Wajeeha
    Asif, Muhammad Iqbal
    Ahmed, Tagwa Kalool Fadlalla
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (05): : 2417 - 2419
  • [9] XEN1101, a novel, potent potassium channel modulator: Interim data from an ongoing, long-term, open-label extension of a Phase 2b study (X-TOLE) in adults with focal onset seizures (FOS)
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M. A.
    Harden, C.
    Qian, J.
    Rosenblut, C. Luzon
    Kenney, C.
    Beatch, G. N.
    EPILEPSIA, 2024, 65 : 184 - 184
  • [10] Quality- of- life improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE)
    Brandt, C.
    Villanueva, V.
    Harden, C.
    Qian, J.
    Luzon-Rosenblut, C.
    Wagner, J.
    Kenney, C.
    Beatch, G. N.
    EPILEPSIA, 2023, 64 : 276 - 276
12